Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients

David Michalovich, Noelia Rodríguez‐Pérez, Sylwia Smolińska, M Pirozyński, David Mayhew, Sorif Uddin, Stephanie Van Horn, Milena Sokołowska, Can Altunbulakli, Andrzej Eljaszewicz, Benoı̂t Pugin, Weronika Barcik, Magdalena Kurnik‐Łucka, Ken Saunders, Karen D. Simpson, Peter Schmid‐Grendelmeier, Ruth Ferstl, Remo Frei, Noriane A. Sievi, Malcolm Kohler, Paweł Gajdanowicz, Katrine Graversen, Katrine Lindholm Bøgh, Marek Jutel, James R. Brown, Cezmi A. Akdiş, Edith M. Hessel, Liam O’MahonyNature Communications 2019 · DOI

Abstract

In order to improve targeted therapeutic approaches for asthma patients, insights into the molecular mechanisms that differentially contribute to disease phenotypes, such as obese asthmatics or severe asthmatics, are required. Here we report immunological and microbiome alterations in obese asthmatics (n = 50), non-obese asthmatics (n = 53), obese non-asthmatics (n = 51) and their healthy counterparts (n = 48). Obesity is associated with elevated proinflammatory signatures, which are enhanced in the presence of asthma. Similarly, obesity or asthma induced changes in the composition of the microbiota, while an additive effect is observed in obese asthma patients. Asthma disease severity is negatively correlated with fecal Akkermansia muciniphila levels. Administration of A. muciniphila to murine models significantly reduces airway hyper-reactivity and airway inflammation. Changes in immunological processes and microbiota composition are accentuated in obese asthma patients due to the additive effects of both disease states, while A. muciniphila may play a non-redundant role in patients with a severe asthma phenotype.

Introduction

Asthma is a heterogeneous condition characterized by various "endotypes" driven by distinct biological mechanisms. Among these, obese asthmatics represent a particularly challenging clinical group, often experiencing more severe symptoms and showing resistance to standard corticosteroid treatments. While both obesity and asthma are known inflammatory conditions, the molecular synergy between them has remained poorly understood. This study investigates how the coexistence of these conditions impacts the systemic immune system and the microbiome across multiple body sites.

To explore these interactions, researchers conducted a comprehensive study involving 202 human participants, categorized into obese asthmatics, non-obese asthmatics, obese non-asthmatics, and healthy controls. The study utilized multi-site microbiome profiling (gut, nose, oral cavity, and lungs), transcriptomics, and proteomics to map the inflammatory landscape of these patients.

The Additive Effect of Obesity and Asthma

A central finding of the research is the "additive effect" observed when obesity and asthma occur together. Rather than simply overlapping, these conditions magnify systemic proinflammatory signatures. Obese asthmatics exhibited the highest serum levels of markers such as C-reactive protein (CRP), Serum Amyloid A (SAA), and fibrinogen compared to all other groups.

Systemic inflammatory markers and pathway enrichment across patient groups, highlighting the additive effect of obesity and asthma.

This systemic disruption is mirrored in the blood's transcriptomic profile, where pathways related to innate immune and inflammatory responses show significantly higher enrichment in the obese asthma group. These findings suggest that the obese asthma phenotype involves a unique, body-wide disruption of microbial-immune crosstalk that extends beyond the lungs.

Microbiome Dysbiosis and Airway Inflammation

The study identified distinct microbial shifts in the lungs and nasal passages of obese asthmatics. Notably, the beneficial bacterium Akkermansia muciniphila was found to be specifically depleted in patients with severe asthma, regardless of their Body Mass Index (BMI). This suggests that A. muciniphila may serve as a critical biomarker for disease severity.

Transcriptomic analysis of bronchial biopsies further revealed that while asthma-related pathways—such as Th2 cell migration and eosinophil granule protein release—were enriched in all asthmatics, obese patients showed additional unique enrichments in pathways like WNT signaling and epithelial-to-mesenchymal transition (EMT).

Enrichment of asthma-specific pathways in bronchial biopsies of obese and non-obese asthmatics.

Therapeutic Potential of Akkermansia muciniphila

To move beyond correlation, the researchers tested the therapeutic potential of A. muciniphila in murine models of both acute and chronic asthma. Oral administration of the viable bacteria significantly reduced airway hyper-reactivity and lung eosinophilia. The mechanism appears to involve a "re-tuning" of the immune system, specifically by increasing the proportion of regulatory T cells (Tregs) and dampening the recruitment of inflammatory cells to the lungs.

Conclusion

This research highlights that obesity and asthma exert a powerful combined effect on the body, worsening systemic inflammation and disrupting the microbiome. The identification of A. muciniphila as a protective agent offers a promising avenue for "next-generation probiotics" aimed at treating severe asthma. However, while the animal models are encouraging, human clinical trials are essential to determine if restoring this microbial balance can improve clinical outcomes for patients suffering from severe or obese asthma phenotypes.

Summary updated

Abstract

In order to improve targeted therapeutic approaches for asthma patients, insights into the molecular mechanisms that differentially contribute to disease phenotypes, such as obese asthmatics or severe asthmatics, are required. Here we report immunological and microbiome alterations in obese asthmatics (n = 50, mean age = 45), non-obese asthmatics (n = 53, mean age = 40), obese non-asthmatics (n = 51, mean age = 44) and their healthy counterparts (n = 48, mean age = 39). Obesity is associated with elevated proinflammatory signatures, which are enhanced in the presence of asthma. Similarly, obesity or asthma induced changes in the composition of the microbiota, while an additive effect is observed in obese asthma patients. Asthma disease severity is negatively correlated with fecal Akkermansia muciniphila levels. Administration of A. muciniphila to murine models significantly reduces airway hyper-reactivity and airway inflammation. Changes in immunological processes and microbiota composition are accentuated in obese asthma patients due to the additive effects of both disease states, while A. muciniphila may play a non-redundant role in patients with a severe asthma phenotype.
BibTeX
@inproceedings{michalovich2019obesity,
  author = {David Michalovich and Noelia Rodríguez‐Pérez and Sylwia Smolińska and M Pirozyński and David Mayhew and Sorif Uddin and Stephanie Van Horn and Milena Sokołowska and Can Altunbulakli and Andrzej Eljaszewicz and Benoı̂t Pugin and Weronika Barcik and Magdalena Kurnik‐Łucka and Ken Saunders and Karen D. Simpson and Peter Schmid‐Grendelmeier and Ruth Ferstl and Remo Frei and Noriane A. Sievi and Malcolm Kohler and Paweł Gajdanowicz and Katrine Graversen and Katrine Lindholm Bøgh and Marek Jutel and James R. Brown and Cezmi A. Akdiş and Edith M. Hessel and Liam O’Mahony},
  title = {{Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients}},
  booktitle = {Nature Communications},
  year = {2019},
  doi = {10.1038/s41467-019-13751-9},
}
Figure